Novo Nordisk’s controlling shareholder to buy Catalent for $16.5 billion

Novo Holdings, the controlling shareholder of Novo Nordisk
NVO,
-1.80%,
said it’s buying Catalent
CTLT,
+2.67%
for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday’s close. The deal is a 39% premium to Catalent’s close before it announced a strategic review. Novo will sell three fill-finish sites to Novo Nordisk shortly after the deal closes. Catalent investor Elliott Investment Management said it supports the deal.